Back to Agenda
Session 3 REPORTS AND CONCLUSION FROM BREAKOUT SESSIONS & EMA UPDATE
Session Chair(s)
Mette Due Theilade Thomsen, PhD
CEO
PIP Adviser, Denmark
Following the feedback from the 3 breakout sessions, the session will be the opportunity for EMA Paediatric Division to provide the attendees with an update on EMA paediatric activities, and to answer specific questions sent by the attendees for EMA and/or PDCO prior to the Conference.
Speaker(s)
Feedback from the Breakout Session 2A
Laura Fregonese, MD, PhD, MSc
European Medicines Agency, Netherlands
Scientific Officer
Heidrun Hildebrand
BAYER, Germany
Paediatric Development Alliance Manager, Paediatric Medicine; Research and De
Feedback from the Breakout Session 2B
Solange Corriol-Rohou, DrMed, MD, PhD
AstraZeneca , France
Senior Director, Global Regulatory Affairs & Policy, R&D, Europe
Feedback from the Breakout Session 2C
Andrew Thomson, PhD, MA, MS
European Medicines Agency, Netherlands
Statistician, Methodology Taskforce
Update from EMA on Paediatric Related Matters and Q&A
Ralph Bax, MD, PhD
European Medicines Agency, Netherlands
Head of the Paediatric Medicines Office
Questions and answers –Paediatric Medicines
Peter Karolyi
European Medicines Agency, Netherlands
Scientific Officer
Koenraad Norga, MD, PhD
Antwerp University Hospital, Belgium
Head of Clinic, Paediatric Oncology
Have an account?